ZORYVE cream effectively alleviates atopic dermatitis symptoms across skin types, confirmed safe and tolerable in Phase 3 trials.

A recent study revealed that ZORYVE (Roflumilast) cream 0.15% effectively alleviates atopic dermatitis symptoms across various skin types, irrespective of race or ethnicity. Phase 3 trials, INTEGUMENT-1 and -2, confirmed the treatment's safety and tolerability among all participants. These findings were shared at the 2024 European Academy of Dermatology & Venereology Congress and conducted by Arcutis Biotherapeutics, Inc.

September 25, 2024
11 Articles